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Biomarker‑estimated flavan‑3‑ol 
intake is associated with lower 
blood pressure in cross‑sectional 
analysis in EPIC Norfolk
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Flavan‑3‑ols are a group of bioactive compounds that have been shown to improve vascular 
function in intervention studies. They are therefore of great interest for the development of dietary 
recommendation for the prevention of cardio‑vascular diseases. However, there are currently 
no reliable data from observational studies, as the high variability in the flavan‑3‑ol content of 
food makes it difficult to estimate actual intake without nutritional biomarkers. In this study, we 
investigated cross‑sectional associations between biomarker‑estimated flavan‑3‑ol intake and blood 
pressure and other CVD risk markers, as well as longitudinal associations with CVD risk in 25,618 
participants of the European Prospective Investigation into Cancer (EPIC) Norfolk cohort. High flavan‑
3‑ol intake, achievable as part of an habitual diet, was associated with a significantly lower systolic 
blood pressure (− 1.9 (− 2.7; − 1.1) mmHg in men and − 2.5 (− 3.3; − 1.8) mmHg in women; lowest vs 
highest decile of biomarker), comparable to adherence to a Mediterranean Diet or moderate salt 
reduction. Subgroup analyses showed that hypertensive participants had stronger inverse association 
between flavan‑3‑ol biomarker and systolic blood pressure when compared to normotensive 
participants. Flavanol intake could therefore have a role in the maintenance of cardiovascular health 
on a population scale.
High blood pressure is a leading disease risk factor globally, and cardiovascular disease (CVD) is a main cause 
of  death1. Therefore, the primary prevention of CVD remains of utmost importance, and changes in dietary 
factors have an important rôle. While dietary recommendations for primary disease prevention have focused 
mainly on dietary patterns and  macronutrients2, increasing attention has been given to a group of non-nutritive 
dietary compounds, bioactives, that are thought to exert a physiological effect and to modulate disease  risk3. 
Flavan-3-ols are a major class of dietary  bioactives4–6, belonging to the group of polyphenolics, commonly found 
in tea, pome fruits, berries, cocoa-derived products and nuts. Accumulating evidence from dietary intervention 
studies shows that the intake of flavan-3-ols improves vascular function in healthy  adults6,7. Indeed, multiple 
clinical dietary intervention studies have demonstrated flavanol-intake related cardiovascular health benefits 
by assessing physiological endpoints including blood pressure, flow-mediated arterial dilation, augmentation 
index, pulse wave velocity and arterial stiffness, as well as  atherogenesis8–10. However, the data currently avail-
able are neither describing effects at sufficient scale nor were derived from long-term investigations and are thus 
insufficient provide the basis for population-based dietary  guidance6. While ongoing large-scale clinical dietary 
intervention studies, such as COSMOS  (NCT0242274511), with specific focus on cardiovascular disease risk and 
outcomes measures that include stroke, myocardial infarction and blood pressure, are intended to close this gap, 
large-scale observational studies can provide crucial information about associations between habitual flavan-3-ol 
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intake and vascular health, especially as these studies usually include a wide range of different foods and bever-
ages and are based on a more heterogeneous population representative of the general public.
Importantly, large-scale observational studies rely on the accurate assessment of intake. To date, all such 
studies aiming to estimate flavan-3-ol intake were based on self-reported dietary data, food frequency question-
naires (FFQs) or food diaries, in combination with food composition data. While this approach, in the absence 
of practicable alternatives, has been tacitly accepted as de facto  standard12–16, it introduces significant limitations 
that substantially affect outcome and interpretation. Self-reported dietary data are subject to a number of limita-
tions and have been demonstrated to be subject to systematic  bias17. Detailed analyses, for example of protein and 
 energy18, but also sugar  intake19, have shown systematic under-reporting. While these methods can provide reli-
able data on dietary patterns and intake of individual foods, these limitations affect the ability to estimate intake 
of individual compounds. This is further exacerbated by the reliance on food composition data, which can only 
provide data on average food content and not the composition of the foods actually consumed. For flavan-3-ols 
but also other compounds found in foods, this approach introduces significant error due to the large variability 
of food  composition20, the effects of  processing21 and differences in bioavailability. Thus, the reliance on food 
composition data to estimate flavan-3-ol intake introduces a considerable measurement error: for example, the 
amount found in tea, one of the main dietary sources in the UK  diet22, ranges from 10 to 330 mg/100 g20. This 
problem is made worse by the common reliance on FFQs, which do not provide sufficient detail on food intake 
to allow an accurate estimate of actual  intake23.
In contrast, nutritional biomarkers, which are assessed by measuring the systemic presence of dietary com-
pounds or their metabolites, have the potential to mitigate the above limitations and thus enable objective and 
accurate estimates of actual  intake24–26. As biomarkers for estimating flavan-3-ol intake were not available previ-
ously, we developed and evaluated at scale nutritional biomarkers to estimate the intake of flavan-3-ols in general, 
based on the flavan-3-ol-derived microbial metabolite 5-3 ′ ,4 ′-dihydroxyphenyl-γ-valerolactone (gVLM)27, and 
one specific for (–)-epicatechin intake, based on structurally related (–)-epicatechin metabolites (SREM)28. The 
biomarkers derived from those metabolites, referred to as gVLM
B
 and SREMB , are surrogate  biomarkers29 when 
assessed in spot urine and therefore allow people to be ranked according to their flavan-3-ol intake.
These novel biomarkers allow rigorous, and more objective and accurate investigations into associations 
between actual flavan-3-ol intake and health in observational cohorts at scales relevant to human populations. 
The primary objective of this study was to investigate cross-sectional associations between biomarker-estimated 
flavan-3-ol intake and blood pressure in more than 25,000 participants of the Norfolk cohort of the European 
Prospective Investigation into Cancer Study (EPIC-Norfolk). The secondary objectives of the study were to 
investigate cross-sectional associations with other cardio-vascular disease risk factors and prospective associa-
tions with cardio-vascular disease risk.
Results
Study population and biomarker. This study was based on data of 25,618 participants (14,026 women, 
55%) of EPIC-Norfolk, after the exclusion of those lost to follow-up (2 women, 1 man), and those who withdrew 
consent (18). Table 1 shows a summary of the baseline characteristics of the study population; more detailed 
data, including information on missing data, are shown as Supplemental Information (Supplementary Tables 1 
and 2). Biomarker concentrations were available for 24,152 participants (13,273 women, 55%). Using specific 
gravity, spot urine samples were adjusted for dilution (25), and these data were available for 21,812 participants 
(11,974 women, 55%), as specific gravity data were not available for all. Missing data were assumed to be missing 
at random and imputed using multiple imputations. The concentrations of both biomarkers, gVLM
B
 for flavan-
3-ols and SREMB for (–)-epicatechin, were correlated (Pearson’s ρ = 0.45).
We have investigated the correlation between biomarker-estimated flavan-3-ol and self-reported food and 
flavan-3-ol intake. There were weak correlations (R2 < 0.2 ) between flavan-3-ol biomarkers and the consumption 
of foods associated with flavan-3-ol intake in the diet of participants in EPIC-Norfolk (Fig. 1), and virtually no 
correlation with flavan-3-ol intake estimated using 7-day food diaries (R2 : 0.01 for gVLM
B
 and 0.07 for SREMB , 
adjusted for energy intake). These findings are consistent with the limitations of estimating bioactive-intake from 
self-reported dietary data described above, in particular the high variability in food composition.
Cross‑sectional associations between flavan‑3‑ol biomarker and blood pressure. The evidence 
available from a wide range of clinical intervention studies show that flavan-3-ols can have a vasculoprotective 
 effect6, but this has never been shown on a large scale in a general population. We have therefore investigated 
the cross-sectional association between flavan-3-ol intake and blood pressure at baseline (Fig.  2). Table 2 shows 
consistent inverse associations between biomarkers of flavan-3-ol ( gVLM
B
 ) and (–)-epicatechin ( SREMB ) intake 
and systolic blood pressure in all models tested. We have further investigated whether the biomarker merely acts 
as a surrogate marker of specific dietary patterns that are associated with blood pressure. Tea is a main dietary 
source of flavan-3-ol in EPIC-Norfolk15, and thus gVLM
B
 and SREMB could both act as a marker of high tea 
or low coffee intake, as there was a strong inverse association between tea and coffee intake (Pearson’s ρ = 0.4); 
similarly, fruits and vegetables can be an important contributor of flavan-3-ols. However, adjusting our data 
analysis additionally for tea and coffee intake, as well plasma vitamin C, as a surrogate marker of fruit and veg-
etable  intake30, associations did not change materially (Table 2). When using gVLM
B
 as biomarker of the intake 
of flavan-3-ol in general, the difference in systolic blood pressure between bottom and top decile of biomarker 
concentrations, the median of the bottom and top quintile, was − 1.9 (− 2.7; − 1.1) mmHg in men and − 2.5 
(− 3.3; − 1.8) mmHg in women (model 5). Compared to the results using gVLM
B
 , the differences in blood pres-
sure between the bottom and top decile were larger when using SREMB as specific biomarker of (–)-epicatechin 
intake, − 2.4 (− 3.3; − 1.5) mmHg in men and − 2.5 (− 3.6; − 2.0) mmHg in women. We found similar associa-
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tions for diastolic blood pressure and biomarker-estimated flavan-3-ol intake, with a difference between the bot-
tom and top decile of approximately 1 mmHg.
Association between flavanol intake and other cardiovascular disease risk markers. We inves-
tigated cross-sectional associations between flavan-3-ol and (–)-epicatechin biomarker and other established 
CVD risk markers (blood lipids and c-reactive protein). There were small differences in blood lipids between the 
bottom and top decile of flavan-3-ol intake assessed with both SREMB and gVLMB , with participants in the top 
decile of biomarker having lower blood cholesterol and LDL concentrations, but higher triglycerides. The asso-
ciations were very similar for SREMB and gVLMB . We did not find any associations of the flavanol biomarkers 
with c-reactive protein concentration (Table 3).
Association with CVD incidence and mortality. High flavan-3-ol intake was associated with lower 
blood pressure and an overall better blood lipid profile and may therefore tenably affect overall CVD risk and 
mortality. Thus, in a secondary analysis, we have investigated associations between gVLM
B
 as biomarker of 
flavan-3-ol intake and CVD risk and CVD and all-cause mortality. After a median of 19.5 (IQR 17.9–20.9) years 
of follow-up, 8030 (31%) participants had died and 13,969 (55%) had developed a cardiovascular disease. Over-
all, there were no consistent, statistically significant associations between flavan-3-ol biomarker and CV disease 
incidence or all cause or CVD mortality (Table 3).
Table 1.  Baseline characteristics and disease incidence of 25,618 participants of EPIC Norfolk. Data shown are 
mean (SD) or absolute number and proportion. More details, including number of missing data, are shown in 
Supplementary Tables 1 and 2. aAdjusted by specific gravity. bNumber at end of follow-up.
All Men Women
n 25,618 11,592 14,026
Age (years) 58.7 (9.3) 59.1 (9.3) 58.4 (9.3)
BMI (kg/m2) 26.4 (3.9) 26.5 (3.3) 26.2 (4.4)
Female (%) 14,026 (55%) – –
Physical activity
Inactive 7853 (31%) 3579 (31%) 4274 (31%)
Moderately inactive 7344 (29%) 2853 (25%) 4491 (32%)
Moderately active 5773 (23%) 2657 (23%) 3116 (22%)
Active 4647 (18%) 2502 (22%) 2145 (15%)
Smoking status
Current 2979 (12%) 1402 (12%) 1577 (11%)
Former 10,751 (42%) 6276 (55%) 4475 (32%)
Never 11,668 (46%) 3833 (33%) 7835 (56%)
Systolic BP (mmHg) 135 (18) 137 (18) 134 (19)
Diastolic BP (mmHg) 83 (11) 84 (11) 81 (11)
Cholesterol (mmol/L) 6.2 (1.2) 6.0 (1.1) 6.3 (1.2)
LDL (mmol/L) 4.0 (1.0) 3.9 (1.0) 4.0 (1.1)
HDL (mmol/L) 1.4 (0.4) 1.2 (0.3) 1.6 (0.4)
Triglycerides (mmol/L) 1.8 (1.1) 2.1 (1.2) 1.6 (1.0)
cRP (mg/L) 3.1 (6.3) 3.0 (6.0) 3.0 (5.9)
Medication user
Lipid lowering drugs 377 (2%) 173 (2%) 204 (2%)
Anti-hypertensive drugs 4798 (19%) 2165 (19%) 2633 (19%)
Biomarker
gVLM ( µmol/L) 9.5 (16.0) 10.5 (16.5) 8.7 (15.5)
gVLM ( µmol/L)a 9.3 (15.7) 10.2 (16.2) 8.6 (15.3)
SREMB ( µmol/L) 2.0 (3.0) 2.2 (3.0) 1.8 (3.0)
SREMB ( µmol/L)a 1.9 (2.9) 2.1 (2.9) 1.8 (2.9)
Disease incidenceb
All CVD 13,969 (55%) 6907 (60%) 7062 (50%)
Mortalityb
All cause 8030 (31%) 4277 (37%) 3753 (27%)
CVD 2613 (10%) 1474 (13%) 1139 (8%)
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Subgroup and sensitivity analyses. We conducted sub-group and sensitivity analyses to further investigate the 
associations between biomarker-estimated flavan-3-ol intake and blood pressure (Fig. 3). We aimed at investigat-
ing whether or not pre-existing CVD or CVD risk would affect the association between systolic blood pressure 
and biomarker-estimated flavan-3-ol intake. Therefore, we compared the difference in systolic blood pressure 
between the top and bottom decile of the flavan-3-ol biomarker in participants with and without pre-existing 
CVD or CVD risk (age, hypertension, overweight, and prevalent CVD at baseline). Hypertensive participants 
had stronger inverse association between flavan-3-ol biomarker and systolic blood pressure when compared to 
normotensive participants, in particular when using SREMB as biomarker. Similar differences were observed 
between hypertensive and normotensive women using gVLM
B
-estimated flavan-3-ol intakes. In addition, the 
difference in systolic blood pressure between the top and bottom decile of the SREMB - and gVLMB-estimated 
flavan-3-ol intake in older men (>60 years) was greater than that in younger men. Finally, significant differences 
were also observed in women with low and high risk of CVD using SREMB as biomarker of flavan-3-ol intake.
Discussion
In participants of EPIC-Norfolk, a large cohort representative of the older general public in  England31, high 
flavan-3-ol intake was associated with a significantly lower systolic and diastolic blood pressure and was inversely 
associated with blood lipids. We did not observe consistent, statistically significant associations between biomark-
ers of flavan-3-ol intake and CVD incidence or mortality.
This study was enabled by recently developed nutritional biomarkers, gVLM
B
 and SREMB , that allow for 
estimating specifically the intake of flavan-3-ols. We have shown previously that gVLM
B
 and SREMB reflect actual 
intake of flavan-3-ols and (–)-epicatechin respectively, yet importantly here we found only a weak correlation 
between biomarker and self-reported food  intake27,28. This finding strongly supports our previous findings of 
the impact of the high variability in food composition on self-reported dietary assessment  methods23. The high 
variability in food composition of many of the main sources of dietary flavan-3-ol make an accurate estimate 
without an analysis of the actual food consumed virtually impossible. For example, food composition  data20 for 
black tea give a range of flavan-3-ol content of 3–64 mg/100 mL, and thus five cups of tea can contain between 
23 and 480 mg of flavan-3-ols. Thus, a person consuming a single cup of tea with high flavan-3-ol content con-
sumes considerably more flavan-3-ols than a person consuming five cups of tea with low flavan-3-ol content. 
A wide variability in food composition has been reported for other foods, too. Indeed, even for foods grown 
on the self-same plant, up to 2.5-fold differences for some nutrients have been  observed32. In contrast, the 
objective nutritional biomarkers used in this study take into account the diversity in the foods consumed and 
differences in bioavailability as they rely on the systemic presence of the respective compounds. The inclusion 
of the main dietary sources of flavan-3-ols and (–)-epicatechin in our statistical models (i.e. tea as well as fruit 
Coffee
Squash
Milk
Porridge & Muesli
Potatoes
Bananas
Citrus
Fruit − Pears
White wine
Juice (citrus)
Chocolate
Berries
Red wine
Tea
Apples
−0.6 −0.4 −0.2 0.0 0.2
A) Men B) Women
Coffee
Squash
Porridge & Muesli
Meat dishes
Milk
Sugars
Bread (brown)
Citrus
Potatoes
White wine
Fruit − other fruits
Salad vegetables
Soups
Fish products coated
Apples
Chocolate
Tea
−0.4 −0.2 0.0 0.2
β β
Figure 1.  Association between biomarker-estimated flavan-3-ol intake ( gVLM
B
 ) and selected food groups from 
7-day diaries. Biomarker-estimated intake was positively associated with tea, wine and apple intake, whereas 
there were inverse associations with coffee and squash (cordial) intake. β are changes in specific gravity-adjusted 
biomarker concentration per SD change of respective reported food group weight, adjusted by total energy 
intake, social class, BMI and age; only food groups with statistically significant association (p < 0.05) are shown.
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and  vegetables22) did not affect outcomes (Table 2, models 3 and 5), which strongly supports the notion that the 
data provided by the nutritional biomarkers is related to the actual intake of bioactive compound and does not 
just reflect dietary patterns.
The two different biomarkers of flavan-3-ol intake used here ( gVLM
B
 and SREMB ), enabled estimating the die-
tary intake of flavan-3-ols27 and the flavan-3-ol (–)-epicatechin28, respectively. The differences between the effect 
sizes estimated with either biomarker were negligible (Tables 2 and 3), and this can to some extent be explained 
by the correlation between the two biomarkers. However, the two biomarkers used in this study originate from 
two distinct metabolic pathways, gVLM
B
 from the catabolism of flavan-3-ols in the gut microbiome, SREMB from 
phase II biotransformation reactions of (–)-epicatechin. Thus, these results pose the question as to whether the 
observed association between flavan-3-ol intake and blood pressure could be explained by the specific intake of 
(–)-epicatechin, as it is the only compound measured with both biomarkers. In this context, previous interven-
tion studies have established a vascular effect for (–)-epicatechin33, and showed that only (–)-epicatechin, but no 
other type of flavan-3-ols exert such  activity34. While larger controlled dietary intervention studies are necessary 
to establish the actual bioactive compound and mode of action, our results clearly show an inverse association 
between flavan-3-ols, including (–)-epicatechin, and blood pressure, and thereby contribute to the data available 
to investigate a causal effect. While the specific molecular mechanisms that underlie the cardiovascular effects of 
flavanols are still under investigation, currently published work in this context indicates that flavanols mediate 
a range of effects on the cellular-/molecular level that impact on endothelial function, nitric oxide-dependent 
arterial dilation, thrombogenic responses, and processes related to vascular inflammation, angiogenesis, and 
endothelial  repair8–10,35–37.
In comparison with the observed associations with blood pressure, the associations with blood lipids were 
rather modest. However, they were of a similar magnitude and direction than those observed in the Minnesota 
Green Tea Trial (MGTT 38), even though flavan-3-ol intakes in EPIC-Norfolk were considerably lower.
Impact on health. In this study, we could demonstrate significant inverse associations between biomark-
ers of flavan-3-ol and (–)-epicatechin intake and blood pressure at baseline. However, there were no consistent, 
statistically significant associations with CVD risk or mortality (CVD related and all-cause) (Table 4). This can 
be explained by the magnitude of difference in systolic blood pressure observed, which would not be expected to 
have significant impact on individual CVD risk (approximately 0.2 percentage points reduction in 10-year CVD 
risk based on QRISK  339).
−1.9 (−2.7; −1.1)-1.9 (-2.7; -1.1) mmHg
125
130
135
140
−5 0 5
log2(gVLM [µM/L])
Sy
st
ol
ic 
BP
 [m
mH
g]
Men
−2.6 (−3.4; −1.8)-2.6 (-3.4; -1.8) mmHg
125
130
135
140
−5 0 5
log2(gVLM [µM/L])
Sy
st
ol
ic 
BP
 [m
mH
g]
Women
Figure 2.  Association between biomarker estimated flavan-3-ol intake and systolic blood pressure. Predicted 
systolic blood pressure (95% confidence interval) in men (left, n=11,592) and women (right, n=14,026) adjusted 
for (model 5) age and BMI, smoking status, physical activity and social class, plasma vitamin C as marker of 
fruit and vegetable intake, tea and coffee intake, baseline health (self-reported diabetes mellitus, myocardial 
infarction, cerebrovascular accident), family history of myocardial infarction, use of anti-hypertensive or lipid-
lowering drugs and menopausal status and hormone replacement therapy in women. The blue lines indicate 
the estimated differences in systolic blood pressure between low (10th percentile) and high (90th percentile) 
concentrations of the biomarker. Biomarker concentrations were adjusted by specific gravity.
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The difference in systolic blood pressure observed here between low and high biomarker concentration in 
the cross-sectional analysis (approximately 2 mmHg) is similar to the reduction in blood pressure observed in 
dietary intervention  studies7. This difference is comparable to those observed with a Mediterranean diet in the 
PREDIMED trial (1.5  mmHg40) or a moderate reduction in salt intake in the DASH-Sodium trial (2.1 mmHg, 
high to intermediate sodium  intake41), and could have considerable impact on health at a population scale. 
However, large-scale dietary intervention studies such as COSMOS  (NCT0242274511) are required to confirm 
whether the observed differences in blood pressure can be explained by differences in flavan-3-ol intake.
A subgroup analyses showed that the association between intake and blood pressure was strongest among 
participants at higher risk of developing cardiovascular diseases, in particular older participants and those with 
existing hypertension, confirming results from previous small-scale dietary intervention  studies7. The associa-
tion between intake and blood pressure therefore follows a progressive  model42, where the strongest effect size 
is found in those with higher blood pressure (Fig. 4). Such a model has also been observed in other dietary 
interventions such as the effect of  potassium43 or  sodium44 intake on blood pressure or the DASH  diet45. In such 
a model, even a small reduction in blood pressure can have a considerable impact on morbidity and mortality 
on a population scale as it reduces the prevalence of hypertension and pre-hypertension, and thus the number 
of people at higher risk of CVD. Indeed, a reduction of 3 mmHg systolic blood pressure can be translated into 
a reduction in all-cause mortality by 3%42,46. Flavanol intake could therefore have a role in the maintenance of 
cardiovascular health on a population scale.
Nutritional interpretation. The differences in blood pressure observed in this study were seen in a popu-
lation with relatively high habitual intakes of flavan-3-ol and not any supplementation as has been used in inter-
vention studies. In this context, it is noteworthy that, while representative of the UK population, the diet of par-
ticipants of EPIC-Norfolk regarding flavan-3-ol intake may not be representative of countries without a strong 
tea culture, including countries in continental Europe and the  US15. Compared to EPIC-Norfolk, it is therefore 
possible that a larger fraction of the population in countries without a tea culture could benefit from increasing 
the intake of flavan-3-ol in their diets. In addition, the question is still open as to whether or not the intake of 
flavan-3-ols beyond the ranges in the EPIC-Norfolk population would be associated with a further reduction in 
blood pressure. In any case, the large variability of flavan-3-ol content in foods precludes the identification of a 
diet that would result in a given increase of flavan-3-ol intake. While incorporating foods and beverages, such as 
tea, apples and berries, would probably increase intake of flavan-3-ols in the diet, it will depend not only on the 
type of food, but also on the actual product variety (species) consumed, the manufacturing conditions in which 
that product was generated and preserved and mode of preparation. This makes more specific recommendations 
impossible.
Table 2.  Associations between biomarker-estimated flavan-3-ol intake and blood pressure. Results shown 
are estimated differences (95% CI) between low (10th percentile) and high (90th percentile) biomarker 
concentrations, using multi-variable linear regression different statistical models. aModel 0: adjusted for age; 
model 1: additionally adjusted for BMI; model 2: additionally adjusted for smoking status, physical activity 
and social class; model 3: additionally adjusted plasma vitamin C as marker of fruit and vegetable intake, 
tea and coffee intake; model 4: model 2, additionally adjusted for baseline health (self-reported diabetes 
mellitus, myocardial infarction, cerebrovascular accident), family history of myocardial infarction, use of anti-
hypertensive or lipid-lowering drugs; model 5: model 3, additionally adjusted for baseline health (self-reported 
diabetes mellitus, myocardial infarction, cerebrovascular accident), family history of myocardial infarction, 
use of anti-hypertensive or lipid-lowering drugs. bAdditionally adjusted for menopausal status and hormone 
replacement therapy. cBiomarker concentrations were adjusted by specific gravity.
Men (n = 11,592) Womenb (n = 14,026)
Systolic BP (mm Hg) Diastolic BP (mm Hg) Systolic BP (mm Hg)
Diastolic BP (mm 
Hg)
gVLMBc
Model 0 a − 1.6 (− 2.4; − 0.8) − 1.0 (− 1.5; − 0.4) − 1.8 (− 2.5; − 1.0) − 1.1 (− 1.6; − 0.6)
Model 1 − 1.8 (− 2.6; − 1.0) − 1.2 (− 1.7; − 0.7) − 2.2 (− 3.0; − 1.5) − 1.4 (− 1.9; − 0.9)
Model 2 − 1.8 (− 2.7; − 1.0) − 1.2 (− 1.7; − 0.6) − 2.3 (− 3.0; − 1.5) − 1.4 (− 1.9; − 0.9)
Model 3 − 2.0 (− 2.8; − 1.2) − 1.3 (− 1.8; − 0.7) − 2.6 (− 3.3; − 1.8) − 1.6 (− 2.0; − 1.1)
Model 4 − 1.8 (− 2.6; − 1.0) − 1.2 (− 1.7; − 0.7) − 2.3 (− 3.0; − 1.5) − 1.4 (− 1.9; − 0.9)
Model 5 − 1.9 (− 2.7; − 1.1) − 1.3 (− 1.8; − 0.7) − 2.5 (− 3.3; − 1.8) − 1.6 (− 2.0; − 1.1)
SREMBc
Model 0 − 1.8 (− 2.6; − 0.9) − 0.7 (− 1.3; − 0.2) − 1.3 (− 2.1; − 0.5) − 0.3 (− 0.8; 0.2)
Model 1 − 2.0 (− 2.8; − 1.2) − 0.9 (− 1.4; − 0.4) − 1.9 (− 2.7; − 1.1) − 0.8 (− 1.2; − 0.3)
Model 2 − 2.1 (− 2.9; − 1.2) − 0.9 (− 1.4; − 0.4) − 2.0 (− 2.7; − 1.2) − 0.8 (− 1.3; − 0.3)
Model 3 − 2.5 (− 3.3; − 1.6) − 1.2 (− 1.7; − 0.6) − 2.9 (− 3.7; − 2.1) − 1.2 (− 1.7; − 0.7)
Model 4 − 2.0 (− 2.8; − 1.2) − 0.9 (− 1.4; − 0.4) − 1.9 (− 2.7; − 1.1) − 0.8 (− 1.3; − 0.3)
Model 5 − 2.4 (− 3.3; − 1.5) − 1.2 (− 1.7; − 0.6) − 2.8 (− 3.6; − 2.0) − 1.2 (− 1.7; − 0.6)
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The biomarkers used in this study were surrogate  biomarkers29. They are used to rank participants according 
to intake, but it is not possible to use them to calculate the actual amount of flavan-3-ol consumed. In order to 
estimate the amount consumed by participants in the top decile of intake, we have therefore used data from 7-day 
food diaries and calculated flavan-3-ol intakes using not only mean food content, as is common practice, but 
the entire range of reported food content (Fig. 5). Participants in the top decile of flavan-3-ol intake consumed 
at least 146 mg/day when using minimum, and 618 mg/day when using maximum food content (260 mg/day 
when using mean food content data) of flavan-3-ols, and at least 4 mg/day (minimum food content) or 138 mg/
day (maximum food content) of (–)-epicatechin (36 mg/day when using mean food content data). While these 
figures provide an initial estimation, further efforts are needed to obtain a more precise number if these data are 
expected to be used for the development of dietary recommendations of flavan-3-ols as bioactive.
Strengths and limitations. The EPIC-Norfolk cohort is ideally placed to investigate potential associations 
between flavan-3-ol intake and cardiovascular disease risk factors, not only because of its size, but also because 
it is set in a population with habitually high flavan-3-ol  intake22. The main strength of the study is the use of 
robustly evaluated nutritional biomarkers to estimate flavan-3-ol27 and (–)-epicatechin28 intake and the use of 
7-day-food diaries for dietary data. A limitation of the study is the reliance on a single spot-urine sample, as 
Table 3.  Associations between biomarker-estimated flavan-3-ol intake and CVD risk markers. Results shown 
are estimated differences (95% CI) between low (10th percentile) and high (90th percentile) biomarker 
concentrations, using multi-variable linear regression different statistical models. aModel 0: adjusted for age; 
model 1: additionally adjusted for BMI; model 2: additionally adjusted for smoking status, physical activity 
and social class; model 3: additionally adjusted plasma vitamin C as marker of fruit and vegetable intake, 
tea and coffee intake; model 4: model 2, additionally adjusted for baseline health (self-reported diabetes 
mellitus, myocardial infarction, cerebrovascular accident), family history of myocardial infarction, use of anti-
hypertensive or lipid-lowering drugs; model 5: model 3, additionally adjusted for baseline health (self-reported 
diabetes mellitus, myocardial infarction, cerebrovascular accident), family history of myocardial infarction, 
use of anti-hypertensive or lipid-lowering drugs. bAdditionally adjusted for menopausal status and hormone 
replacement therapy. cBiomarker concentrations were adjusted by specific gravity.
Cholesterol (mmol/L) HDL (mmol/L) LDL (mmol/L) Triglycerides (mmol/L) CRP (mg/L)
Men (n = 11,592)
gVLMBc
Model 0 a − 0.1 (− 0.1; 0.0) 0.0 (0.0; 0.0) − 0.1 (− 0.1; 0.0) 0.1 (0.0; 0.1) − 0.1 (− 0.5; 0.2)
Model 1 − 0.1 (− 0.1; 0.0) 0.0 (0.0; 0.0) − 0.1 (− 0.1; 0.0) 0.1 (0.0; 0.1) − 0.2 (− 0.5; 0.2)
Model 2 − 0.1 (− 0.1; 0.0) 0.0 (0.0; 0.0) − 0.1 (− 0.1; 0.0) 0.1 (0.0; 0.1) − 0.2 (− 0.5; 0.1)
Model 3 − 0.1 (− 0.1; 0.0) 0.0 (0.0; 0.0) − 0.1 (− 0.1; 0.0) 0.0 (0.0; 0.1) − 0.2 (− 0.6; 0.1)
Model 4 − 0.1 (− 0.1; 0.0) 0.0 (0.0; 0.0) − 0.1 (− 0.1; 0.0) 0.1 (0.0; 0.1) − 0.2 (− 0.5; 0.2)
Model 5 − 0.1 (− 0.1; 0.0) 0.0 (0.0; 0.0) − 0.1 (− 0.1; 0.0) 0.1 (0.0; 0.1) − 0.2 (− 0.5; 0.1)
SREMBc
Model 0 − 0.1 (− 0.2; − 0.1) 0.0 (0.0; 0.0) − 0.2 (− 0.2; − 0.1) 0.1 (0.1; 0.2) 0.2 (− 0.2; 0.5)
Model 1 − 0.1 (− 0.2; − 0.1) 0.0 (0.0; 0.0) − 0.2 (− 0.2; − 0.1) 0.1 (0.1; 0.2) 0.1 (− 0.2; 0.5)
Model 2 − 0.1 (− 0.2; − 0.1) 0.0 (0.0; 0.0) − 0.2 (− 0.2; − 0.1) 0.1 (0.1; 0.2) 0.1 (− 0.3; 0.4)
Model 3 − 0.1 (− 0.1; 0.0) 0.0 (0.0; 0.0) − 0.1 (− 0.2; − 0.1) 0.1 (0.0; 0.2) 0.0 (− 0.4; 0.3)
Model 4 − 0.1 (− 0.2; − 0.1) 0.0 (0.0; 0.0) − 0.2 (− 0.2; − 0.1) 0.1 (0.1; 0.2) 0.1 (− 0.3; 0.4)
Model 5 − 0.1 (− 0.1; 0.0) 0.0 (0.0; 0.0) − 0.1 (− 0.2; − 0.1) 0.1 (0.1; 0.2) 0.0 (− 0.3; 0.4)
Womenb (n = 14,026)
gVLMBc
Model 0 − 0.1 (− 0.1; 0.0) 0.0 (− 0.1; 0.0) − 0.1 (− 0.1; 0.0) 0.1 (0.1; 0.2) 0.3 (0.0; 0.6)
Model 1 − 0.1 (− 0.1; 0.0) 0.0 (0.0; 0.0) − 0.1 (− 0.1; 0.0) 0.1 (0.0; 0.1) 0.2 (− 0.1; 0.5)
Model 2 − 0.1 (− 0.1; 0.0) 0.0 (0.0; 0.0) − 0.1 (− 0.1; 0.0) 0.1 (0.0; 0.1) 0.2 (− 0.1; 0.5)
Model 3 − 0.1 (− 0.1; 0.0) 0.0 (0.0; 0.0) − 0.1 (− 0.1; 0.0) 0.1 (0.0; 0.1) 0.1 (− 0.2; 0.4)
Model 4 − 0.1 (− 0.1; 0.0) 0.0 (0.0; 0.0) − 0.1 (− 0.1; 0.0) 0.1 (0.0; 0.1) 0.2 (− 0.1; 0.5)
Model 5 − 0.1 (− 0.1; 0.0) 0.0 (0.0; 0.0) − 0.1 (− 0.1; 0.0) 0.1 (0.0; 0.1) 0.1 (− 0.2; 0.4)
SREMBc
Model 0 0.0 (− 0.1; 0.1) 0.0 (0.0; 0.0) 0.0 (− 0.1; 0.0) 0.2 (0.1; 0.2) 0.4 (0.1; 0.7)
Model 1 0.0 (− 0.1; 0.0) 0.0 (0.0; 0.0) − 0.1 (− 0.1; 0.0) 0.1 (0.1; 0.2) 0.3 (0.0; 0.6)
Model 2 0.0 (− 0.1; 0.0) 0.0 (0.0; 0.0) − 0.1 (− 0.1; 0.0) 0.1 (0.1; 0.2) 0.3 (0.0; 0.6)
Model 3 0.0 (− 0.1; 0.1) 0.0 (0.0; 0.0) − 0.1 (− 0.1; 0.0) 0.1 (0.1; 0.1) 0.1 (− 0.3; 0.4)
Model 4 0.0 (− 0.1; 0.0) 0.0 (0.0; 0.0) − 0.1 (− 0.1; 0.0) 0.1 (0.1; 0.2) 0.3 (0.0; 0.6)
Model 5 0.0 (− 0.1; 0.1) 0.0 (0.0; 0.0) − 0.1 (− 0.1; 0.0) 0.1 (0.1; 0.1) 0.1 (− 0.2; 0.4)
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Figure 3.  Subgroup- and sensitivity analysis, comparing estimated differences in systolic blood pressure 
between sex-specific bottom (p10) and top (p90) decile of biomarker-estimated flavan-3-ol intake. Models were 
adjusted by age, BMI, smoking status, physical activity and social class, and additionally for menopausal status 
and hormone-replacement therapy for women. †Hypertensive: systolic BP ≥ 140 mmHg; §normal weight: BMI 
≤ 25 kg/m2 ; ‡low risk: no baseline prevalence of diabetes or heart disease, no family history of heart disease, no 
anti-hypertensive or lipid-lowering drug use at baseline.
Table 4.  Associations between gVLM
B
 as biomarker of flavan-3-ol intake and CVD incidence and CVD and 
all-cause mortality. Results shown are estimated differences (HR, 95% CI) between low (10th percentile) and 
high (90th percentile) biomarker concentrations, using different statistical models. aModel 0: stratified by 
age-decade; model 1: additionally adjusted for BMI; model 2: additionally adjusted for smoking status, physical 
activity and social class; model 3: additionally adjusted plasma vitamin C as marker of fruit and vegetable 
intake, tea and coffee intake; model 4: model 2, additionally adjusted for baseline health (self-reported diabetes 
mellitus, myocardial infarction, cerebrovascular accident), family history of myocardial infarction, use of anti-
hypertensive or lipid-lowering drugs; model 5: model 3, additionally adjusted for baseline health (self-reported 
diabetes mellitus, myocardial infarction, cerebrovascular accident), family history of myocardial infarction, 
use of anti-hypertensive or lipid-lowering drugs. bAdditionally adjusted for menopausal status and hormone 
replacement therapy. cBiomarker concentrations were adjusted by specific gravity.
Men (n = 11,592) Womenb (n = 14,026)
All-cause CVD All-cause CVD
Incidence
Model 0 a – 1.04 (0.97; 1.11) – 1.06 (0.99; 1.13)
Model 1 – 1.03 (0.96; 1.10) – 1.03 (0.97; 1.10)
Model 2 – 1.02 (0.95; 1.09) – 1.02 (0.95; 1.09)
Model 3 – 1.01 (0.95; 1.08) – 1.01 (0.94; 1.07)
Model 4 – 1.04 (0.98; 1.11) – 1.02 (0.96; 1.09)
Model 5 – 1.04 (0.98; 1.11) – 1.01 (0.95; 1.08)
Mortalityc
Model 0 0.99 (0.91; 1.08) 0.99 (0.86; 1.15) 1.00 (0.92; 1.09) 1.02 (0.87; 1.20)
Model 1 0.98 (0.90; 1.07) 0.99 (0.85; 1.14) 1.00 (0.91; 1.09) 1.01 (0.86; 1.19)
Model 2 0.97 (0.89; 1.05) 0.98 (0.84; 1.13) 0.97 (0.89; 1.06) 0.99 (0.85; 1.16)
Model 3 0.96 (0.88; 1.05) 0.97 (0.83; 1.12) 0.97 (0.88; 1.05) 1.00 (0.86; 1.18)
Model 4 0.98 (0.90; 1.07) 1.01 (0.88; 1.17) 0.97 (0.89; 1.06) 1.01 (0.86; 1.18)
Model 5 0.98 (0.90; 1.07) 1.01 (0.87; 1.17) 0.97 (0.89; 1.06) 1.03 (0.87; 1.20)
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Figure 4.  Distribution of systolic blood pressure of participants of EPIC Norfolk in the bottom (p10) and top 
(p90) decile of flavan-3-ol intake (estimated by gVLM
B
 ). Approximately 40% of participants in the bottom 
decile (p10) were hypertensive or pre-hypertensive (systolic blood pressure geq 140 mmHg), compared to 33% 
in the top decile.
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Food content data
Figure 5.  Distribution of flavan-3-ol and (–)-epicatechin intake in EPIC Norfolk, estimated using 7-day food 
diaries and minimum (green), mean (red) and maximum (purple) food composition  data20. The graph indicates 
the 90th percentile (p90) used as high intake in this study (146 mg/day when using minimum food content 
data, 270 mg/day when using mean food consumption data as is common practice and 618 mg/day when using 
maximum food composition data), as well as the amounts used for the EFSA approved health claim (200 mg/
day)47 and the COSMOS study (600 mg/day)11.
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multiple samples would have provided a more representative estimation of habitual intake. The plasma half-life 
of gVLM, approximately 6 h, is sufficient to achieve steady-state like conditions with regular  consumption27. As 
the main source of flavan-3-ol intake in a UK cohort is  tea22, which is consumed regularly in a UK population, 
it can provide information on longer term intake. The half-life of SREM is considerably shorter, 2 h, and the 
biomarker therefore reflects mainly short-term intake. Further limitations are the largely cross-sectional nature 
and the inability to derive actual intake from surrogate biomarkers, only allowing the ranking of participants 
according to  intake29.
Conclusions. This study demonstrates the importance of nutritional biomarkers to estimate intake of plant 
bioactives to investigate associations between intake and disease risk, as only biomarkers can provide reliable 
information on actual bioactive intake. It also raises the important question of the impact of the variability in 
food composition on nutritional research and dietary assessment. The results of our study show a significant 
and biomedically relevant inverse association between biomarkers of flavan-3-ol intake and blood pressure in a 
free-living general population with a wide range of flavan-3-ol intake from their habitual diet. The observed dif-
ference is approximately comparable to that of adherence with the Mediterranean Diet or moderate salt reduc-
tion, and likely to have a considerable impact on a population scale. In the context of an ageing population 
and increased prevalence of chronic diseases, these findings hold promise for the prevention of cardiovascular 
disease through dietary approaches.
Methods
Study population. Between 1993 and 1997, 30,447 women and men aged between 40 and 75 years were 
recruited for the Norfolk cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC) 
study, and 25,633 attended a health  examination31. Health and lifestyle characteristics, including data on smok-
ing, social class and family medical history, were assessed by questionnaire. Height and weight measurements 
were collected following a standardized protocol by trained research nurses. Physical activity, representing 
occupational and leisure activity, was assessed using a validated  questionnaire48. Blood pressure was measured 
by using a non-invasive oscillometric blood pressure monitor (Acutorr; Datascope Medical, Huntingdon, UK; 
validated against sphygmomanometers every 6 months) after the participant had been seated in a comfortable 
environment for 5 min. The arm was horizontal and supported at the level of the mid-sternum; the mean of two 
readings was used for analysis. Non-fasting blood samples were taken by venepuncture and stored in serum 
tubes in liquid nitrogen. Serum levels of total cholesterol were measured on fresh samples with the RA 1000 
autoanalyzer (Bayer Diagnostics, Basingstoke, UK). Plasma vitamin C was measured using a fluorometric assay 
as described  previously49. Non-fasting spot urine samples were collected during the health examination and 
stored at − 20 ◦ C until analysis. Samples were collected throughout the day, and there were no consistent associa-
tions between collection time and biomarker concentration. Diet was assessed by 7-day diary (7DD), whereby 
the first day of the diary was completed as a 24-h recall (24HDR) with a trained interviewer and the remainder 
completed during subsequent days. Diary data were entered, checked and calculated using the in-house dietary 
assessment software DINER (Data into Nutrients for Epidemiological Research) and  DINERMO50. Flavan-3-ol 
intake (the sum of epicatechin, catechin, epicatechin-3-O-gallate, catechin-3-O-gallate and proanthocyanidins) 
was estimated as described  previously15; minimum and maximum estimated flavan-3-ol intake was estimated 
using the minimum and maximum food content data provided by Phenol Explorer und USDA  databases20.
The study was approved by the Norwich Local Research Ethics Committee and all participants gave written, 
informed consent and all methods were carried out in accordance with relevant guidelines and regulations.
Flavan‑3‑ol biomarker. We have used two different biomarkers to estimate flavan-3-ol intake, one based 
on the flavan-3-ol-derived microbial metabolite 5-3 ′ ,4 ′-dihydroxyphenyl-γ-valerolactone (gVLM)27, and one 
based on structurally related (–)-epicatechin metabolites (SREM)28: gVLM
B
 that includes the metabolites 5-(3 ′
,4 ′-dihydroxyphenyl)-γ-valerolactone-3 ′-O-glucuronide (gVL3G) and 5-(3 ′ ,4 ′-dihydroxyphenyl)-γ-valerol-
actone-3 ′-sulphate (gVL3S), and SREMB that includes the metabolites (–)-epicatechin-3 ′-glucuronide (E3G), 
(–)-epicatechin-3 ′-sulfate (E3S) and 3 ′-O-methyl-(–)-epicatechin-5-sulfate (3Me5S). gVLM
B
 are specific for 
estimating the intake of flavan-3-ols in general, including (±)-epicatechin, (±)-catechin, (±)-epicatechin-3-O-
gallate, (±)-catechin-3-O-gallate and procyanidins and excluding the flavan-3-ols gallocatechin, epigallocat-
echin, gallocatechin-3-O-gallate, epigallocatechin-3-O-gallate, theaflavins and  thearubigins27. SREMB are spe-
cific for (–)-epicatechin  intake28. Spot urine samples were collected during the baseline health examination and 
stored in glass bottles at 20 ◦ C until analysis. Stability analyses confirmed that biomarkers are stable under 
these  conditions28. Samples were analysed in random order using the method described  previously27,28, with 
automated sample preparation (Hamilton Star robot; Hamilton, Bonaduz, Switzerland). Briefly, 60 µ L spot urine 
sample and internal standard solutions (2.5 µ M 13C2D2-5-(3 ′ ,4 ′-dihydroxyphenyl)-γ-valerolactone-3 ′-sulphate, 
D2/D3-epicatechin-3 ′-β-D-glucuronide, 50:50 mix)) were combined, filtered (Impact Protein Precipitation filter 
plate, Phenomenex, Macclesfield, UK; centrifuged for 2 min at 500 × g at room temperature and stored at 20 
◦ C until analysis. Samples were then separated by liquid chromatography (Acquity, Waters, Elstree, UK) using 
a C18 column (Kinetex C18 200 × 2.1 mm, 1.7 µ m, with 0.5 µ m Krudcatcher, Phenomenex, Macclesfield, UK) 
and detected by electrospray ionisation tandem mass spectrometry (Applied Biosystems API 4000, Sciex, War-
rington, UK) in negative ion mode. The spray voltage was − 4500 V and the source temperature was 600 ◦ C. 
Samples were quantified using calibration standards prepared in flavan-3-ol-metabolite free urine samples using 
the peak area ratio of analyte and internal standard. Each batch included two replicates of quality control sam-
ples with three different concentrations: low QC (0.3 µM), medium QC (2.5 µ M for SREMB , 25 µ M for gVLMB ) 
and high QC (3.8 µ M for SREMB , 38 µ M for gVLMB ) and usual acceptance criteria for each batch were that at 
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least one QC at each concentration and four out of the six QCs were within 15% of the theoretical concentration. 
The accuracy of the method was better than 5%, precision of the method (%CV) below 12% for all analytes. The 
results for 224 randomly inserted duplicate samples showed a high correlation (R2 = 0.92) with a mean differ-
ence of 1 (95% CI − 0.04; 6.9) µmol/L. We did not observe any time-dependent change in method performance.
Concentrations below the lower limit of quantification (LLOQ, 0.1 µ M) were used for the analysis to avoid the 
bias of substituting a range of values by a single value. Concentrations below the limit of detection were assigned 
a value of 0.001 µ M. Concentrations were adjusted by specific gravity for dilution as the endpoint of the analysis, 
systolic blood pressure, was strongly correlated with urinary  creatinine51.
Incident CVD events and mortality. All participants were followed up for fatal and nonfatal CVD events, 
and the present study includes events until 31 March 2016, covering a median follow-up time of 19.5 (IQR 17.9; 
20.9) years. Cause-specific hospital admission was determined via ENCORE (East Norfolk Commission Record, 
the hospital admissions database kept by the East Norfolk Health Commission)52 with the individuals’ unique 
National Health Service (NHS) number. All individuals were flagged by the UK Office of National Statistics 
(ONS) for death certification and trained nosologists coded death certificates according to the International 
Classification of Disease (ICD). The disease endpoints of this study was the first CVD event [defined as ICD 
410–448 (ICD 9) or ICD I10–I79 (ICD 10)].
Data analysis. Data analyses were carried out using R 3.653, using the packages rms54 for regression anal-
yses, ggplot255 and gridExtra56 for the generation of graphics. Regression analyses were conducted using the 
fit.mult.impute function with either ols (cross-sectional analyses) or cph (prospective analyses) as regression 
function. We have used the Wald statistics calculated by the rms anova function to investigate the relationship 
between dependent and independent variables, and to test for linearity.  tableone57 was used to prepare tables. 
Unless indicated otherwise, results are shown with 95% confidence intervals.
Descriptive statistics. Descriptive characteristics of the study population were summarised using mean 
(standard deviation) for continuous variables and frequency (percentage) for categorical variables.
Missing values. Missing values (Supplemental Table 1) were assumed to be missing at random and were 
imputed using multiple imputation using the aregImpute  algorithm54, which uses predictive mean matching 
with optional weighted probability sampling. We have used different imputed datasets: for the analysis of cross-
sectional associations with the primary endpoint (blood pressure), for the analysis with cross-sectional asso-
ciations with the secondary endpoints (blood lipids), and one for each prospective association with disease 
endpoints and mortality. In each imputation, we created 50 imputed, using restricted cubic splines (3 knots) and 
not assuming linearity, including all variables used in the final analysis. For prospective analyses, we have also 
included the Nelson-Aalen  estimator58. There were no meaningful differences when comparing results obtained 
from the full data set with complete cases analyses in cross-sectional data (Supplementary Tables 3 and 4).
Data transformation. Biomarker data were positively skewed (log-normal distribution) and therefore 
log2-transformed data were used for all analyses. Restricted cubic splines (3 knots, outer quantiles 0.1 and 0.9; 
using the rcs  function54) were used for all continuous variables unless indicated otherwise.
Association between biomarker and self‑reported intake. Associations between biomarker-esti-
mated flavan-3-ol intake and different food groups were investigated using multivariable regression analysis, 
using z-scores of self-reported food group intake (n = 96) as independent variables. Models were adjusted for 
age, BMI, social class and energy intake, and stratified by sex.
Cross‑sectional analyses. In cross-sectional analyses, stratified by sex, we investigated associations 
between the flavan-3-ol biomarker, (specific gravity adjusted concentration, log2-transformed), as an independ-
ent variable and systolic and diastolic blood pressure (mmHg) using multiple regression analyses. Statistical 
models were selected a priori based on likely confounders. Model 0 was adjusted for age (continuous; years); 
model 1 additionally for BMI (continuous; kg/m2 ) ; model 2: additionally for smoking status (categorical; never, 
ever, former), physical activity (categorical; inactive, moderately inactive, moderately active, active) and social 
class (categorical; unclassified, A, B, C1, C2, D, E); model 3: additionally for plasma vitamin C as marker of fruit 
and vegetable intake (continuous, µM), tea and coffee intake (continuous, g/day, derived from 7-day diary); 
model 4: model 2, additionally adjusted for baseline health (self-reported diabetes mellitus, myocardial infarc-
tion, cerebrovascular accident), family history of myocardial infarction, use of anti-hypertensive or lipid-low-
ering drugs (all categorical; yes, no); model 5: model 3, additionally adjusted for baseline health (self-reported 
diabetes mellitus, myocardial infarction, cerebrovascular accident), family history of myocardial infarction, 
use of anti-hypertensive or lipid-lowering drugs (all categorical; yes, no). Analyses in women were additionally 
adjusted for menopausal status [categorical; pre-menopausal, peri-menopausal (2 categories), post-menopausal] 
and hormone replacement therapy (categorical; current, former, never).
Association between biomarker and disease risk and mortality. In prospective analyses, we inves-
tigated associations between the flavan-3-ol biomarker, (specific gravity adjusted concentration, log2-trans-
formed), as an independent variable and disease risk (CVD, IHD, MI and Stroke), and mortality using Cox 
regression analyses. The proportional hazard assumptions has been tested using the cox.zph function and was 
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met. Statistical models were selected a priori based on likely confounders. All models were stratified by age (as 
decade) at baseline, but age was not included as a covariable. Otherwise, models were the same as described for 
cross-sectional analyses.
Sensitivity and complete cases analyses. Post-hoc sensitivity analyses were conducted by restricting 
the study population to those without any self-reported disease or disease risk at baseline and post-menopausal 
women. The same analyses as described above were also conducted on a subsample of the study population for 
whom all data were available (complete cases analysis).
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